Novartis Fabhalta gets positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria Ruchika Sharma24 March 2024 2:30 PM ISTBasel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
Submit Interim Safety, Efficacy Data: CDSCO Panel Tells Novartis on Crizanlizumab Dr. Divya Colin20 March 2024 6:00 PM ISTNew Delhi: Reviewing the status of the ongoing studies of Crizanlizumab concentrate for solution for infusion 10mg/mL (100mg/10mL), the Subject Expert...
Modify Clinical study protocol of Iptacopan study in aHUS: CDSCO Panel Tell Novartis Dr. Divya Colin17 March 2024 5:15 PM ISTNew Delhi: Reviewing the Phase IIIb clinical trial study protocol of Iptacopan, the Subject Expert Committee (SEC) functional under the Central...
Former Novartis India Chief Ranjit Shahani no more Ruchika Sharma11 March 2024 3:22 PM ISTNew Delhi: Former Vice Chairman and Managing Director of Novartis India and Chairman of JB Pharmaceuticals, Ranjit Shahani has passed...
Britain health regulator revokes conditional marketing authorisation for Novartis sickle cell drug Adakveo Ruchika Sharma22 Feb 2024 11:20 AM ISTSickle cell disease is a genetic disorder in which misshapen blood cells cause strokes, organ damage, severe pain and early death.
Will Novartis continue business in India? Global Drug major strategic review to decide Ruchika Sharma17 Feb 2024 2:16 PM ISTDrug major Novartis AG has announced a strategic review of Novartis India Ltd, a public company listed on the BSE.The strategic review will include an...
CDSCO Panel Approves Novartis Protocol Amendment Proposal For Multiple Sclerosis Drug Ofatumumab Dr. Divya Colin11 Feb 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis to acquire MorphoSys AG for EUR 68 per share or aggregate of EUR 2.7bn in cash Ruchika Sharma6 Feb 2024 12:30 PM ISTBasel: Novartis has announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a...
CDSCO Panel grants Novartis Protocol Amendment proposal for Remibrutinib study in Relapsing Multiple Sclerosis Dr. Divya Colin5 Feb 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis Gets CDSCO Panel Nod to Study XXB750 in Patients With Heart Failure Dr. Divya Colin2 Feb 2024 6:00 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel Grants Novartis Protocol Amendment Proposal For anti-cholesterol drug Inclisiran Dr. Divya Colin28 Jan 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
EU regulator starts safety review of CAR-T cancer cell therapies Ruchika Sharma15 Jan 2024 9:00 AM ISTThe European Union's drug watchdog has said it had started a review into the safety risks associated with cancer cell therapies made by companies such...
